Lung Cancer Trials Ask AI to find trials
CompletedPhase 1 / Phase 2NCT04349267
Official study title

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

Study summary

The purpose of this study is to evaluate BMS-986315 alone and in combination with nivolumab or cetuximab in participants with advanced solid tumors.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedBMS-986315 and nivolumab

Plus 1 other study approaches.

Who it may be forAdvanced Solid Tumor

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Dec 17, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 1 / Phase 2

Interventional

Where is it offered?8 U.S. locations

Locations may change over time.

Who runs it?Bristol-Myers Squibb

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1 / Phase 2
Sponsor
Bristol-Myers Squibb
Interventions being studied
Biological: BMS-986315; Biological: nivolumab; Biological: cetuximab
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach
Immunotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Participants must have histologic confirmation of advanced (metastatic, recurrent, and/or unresectable) squamous cell carcinoma of the head and neck (SCCHN), nonsmall cell lung cancer (NSCLC), or renal cell cancer (RCC) with measurable disease per RECIST 1.1
  • Participants expected to have received standard of care therapies including an available PD-(L)1 inhibitor
  • Eastern cooperative oncology group performance status of 0 or 1
  • Women of childbearing potential must agree to follow methods of contraception
Reasons someone may not be able to joinExclusion criteria
  • Participants with active, known or suspected autoimmune disease
  • Participants with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications
  • Uncontrolled or significant cardiovascular disease
  • History of or with active interstitial lung disease or pulmonary fibrosis
  • Prior participation in anti-natural killer cell receptor (anti-NKG2A) clinical study
  • History of allergy or hypersensitivity to study drug components Other protocol-defined inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Local Institution - 0028Sioux Falls, South Dakota
  • Local Institution - 0001Germantown, Tennessee
  • Local Institution - 0014Edmonton, Alberta
  • Local Institution - 0011Vancouver, British Columbia
  • Local Institution - 0004Toronto, Ontario
  • Local Institution - 0005Montreal, Quebec
  • Local Institution - 0013Ottawa
  • Local InstitutionMexico City, Mexico City

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Dec 17, 2025. Always confirm current availability with the study team.

View original record ↗